Skip to main content
VISIT JANSSEN GLOBAL
 
 
 

EMEA
change location▼

Search
Search

Welcome to Janssen Europe, Middle-East and Africa

VISIT JANSSEN GLOBAL

Janssen EMEA › Media Center

Media Center

The Media Center is intented to provide resources for media professionals only. It is not inteded for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Mar 22, 2019

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Mar 20, 2019

NEW PHASE 3 STELARA® (USTEKINUMAB) DATA SHOW POSITIVE RESULTS AS MAINTENANCE THERAPY IN ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Jan 21, 2019

JANSSEN SUBMITS APPLICATION TO EUROPEAN MEDICINES AGENCY SEEKING APPROVAL OF STELARA® (USTEKINUMAB) FOR TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS 

Jan 21, 2019

New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48 

Jan 17, 2019

Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Dec 23, 2018

Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) Split Dosing Regimen 

View more Press Releases

Media Backgrounders

Waldenström’s Macroglobulinemia (WM)

Stelara MOA infographic

The Role Of The Immune System In Crohn’s Disease

About Crohn’s Disease Backgrounder

Mantle Cell Lymphoma (MCL)

Multiple Myeloma (MM)

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL